tions), though the evidence base for any treatment in acute heart failure is weak. [1] [2] [3] [4] [5] The endothelins are peptides with a powerful vasoconstrictor action as well as other effects that could be harmful in heart failure. [6] [7] [8] Higher plasma endothelin concentrations also predict worse clinical outcomes in patients with heart failure. [6] [7] [8] Tezosentan is a short-acting endothelin A-type and B-type receptor antagonist developed for intravenous use. [9] [10] [11] [12] [13] It is a potent vasodilator that reduces systemic vascular resistance and PCWP and increases cardiac output in a dose-dependent manner. [9] [10] [11] [12] [13] The Value of Endothelin Receptor Inhibition With Tezosentan in Acute Heart Failure Studies (VERITAS) were designed to test the hypothesis that tezosentan would have a favorable effect on symptoms and clinical outcomes in patients with acute heart failure.
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METHODS
The VERITAS program consisted of 2 independent, identical, and concurr e n t s t u d i e s ( V E R I T A S -1 a n d VERITAS-2) conducted from April 2003 through January 2005, the design of which has been described in detail. 14 The study was approved by the ethics committee/independent review board of each participating hospital.
The steering committee, a group of advisors, and the sponsor designed the trials and also met periodically to assess the progress of the study, address operational issues, and, at the end of the study, interpret the results. The independent data and safety monitoring board (DSMB) 14 met periodically to review safety data and, after interim analysis, to review efficacy data. The DSMB was empowered to recommend early termination of the study program for futility (see below) or if major concerns arose about the safety of tezosentan. Analysis of data for the DSMB was carried out by an independent statistical group.
Study Design
VERITAS-1 and VERITAS-2 were randomized, double-blind, placebocontrolled, parallel-group studies (FIGURE 1). Patients were eligible if they were 18 years or older and met the inclusion and exclusion criteria. The key inclusion criteria were admission to hospital with acute heart failure within the previous 24 hours and persistence of dyspnea at rest. The patient's report of dyspnea had to be supported by a respiratory rate of at least 24/min. The investigator's clinical diagnosis of heart failure had to be supported by at least 2 of 4 criteria: (1) elevated concentration of B-type natriuretic peptide (BNP) or N-terminal pro-BNP, (2) pulmonary edema on physical examination, (3) radiologic pulmonary congestion or edema, or (4) left ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] Ͻ40% or wall motion index Յ1.2). If the patient had a pulmonary artery catheter, the cardiac index (measured as L/min per m 2 ) had to be 2.5 and the PCWP 20 mm Hg or greater.
The patient must also have received at least 1 dose of an intravenous diuretic 24 hours or less and 2 hours or more prior to initiation of the study drug (or an infusion of diuretic at a constant rate for Ն2 hours). If other intravenous treatments were initiated before the start of study drug, their dose had to be stable for 2 hours or more for vasodilators, sympathomimetics, or calcium sensitizers or for 4 hours for phosphodiesterase inhibitors and nesiritide.
The exclusion criteria have been described in detail and included cardiogenic shock within 48 hours, STsegment elevation myocardial infarction, ongoing ischemia or administration of a thrombolytic agent, hypotension (systolic blood pressure Ͻ100 mg Hg in patients not receiving a vasodilator or Ͻ120 mm Hg in those receiving a vasodilator), anemia (hemoglobin concentration Ͻ10 g/dL, hematocrit Ͻ30%), or renal dysfunction (creatinine concentration Ͼ2.5 mg/dL [to convert to µmol/L, multiply by 88.4]).
14 Information on race/ ethnicity was collected for each patient by means of an investigator check box.
Study Treatment
Afterobtainingwritteninformedconsent, patientswererandomized24hoursorless from admission to receive an infusion of either placebo or tezosentan, 5 mg/h for 30minutes,followedby1mg/hforatleast 24 (and up to 72) hours. Patients in the placebo group received an identical volumeofsalineinfusion(104mLforthefirst 24 hours). Patients and study investigators were blinded to study assignment.
Primary End Points
The primary end point of each individual VERITAS study was the change from baseline in dyspnea over the first 24 hours of treatment, measured at 3, 6, and 24 hours as the area under the curve. Dyspnea was assessed by each patient using a visual analog scale (VAS) consisting of a 10-cm vertical line with the phrase "I am not breathless at all" at the bottom of the scale and "I am the most breathless I have ever been" at the top. The VAS was scored from 0 to 100, but the patient was unaware of the numerical value of his or her response.
The primary efficacy end point of the combined studies was the incidence of death or worsening heart failure at 7 days. Worsening heart failure could occur during the index admission or after discharge. Worsening heart failure occurring during initial hospital admission was defined either as the development of pulmonary edema, cardiogenic shock, or other evidence of worsening heart failure or as lack of improvement in the patient's heart failure with treatment (treatment failure). Both definitions required at least 1 of the following: (1) initiation of new intravenous therapy, (2) reinstitution of prior intravenous therapy, (3) increase in current intravenous therapy for heart failure, (4) implementation of mechanical circulatory (eg, intra-aortic balloon pump) or ventilatory (including continuous positive airway pressure) support, or (5) use of ultrafiltration, hemofiltration, or hemodialysis. Worsening heart failure occurring after the index admission was defined either as an unplanned visit to an emergency department because of worsening heart failure (pulmonary edema, cardiogenic shock, or other evidence of worsening failure) or as unplanned admission because of worsening heart failure. Both definitions required at least 1 of the following: (1) administration of intravenous treatment for heart failure, including diuretic, vasodilator, or inotropic agents; (2) implementation of mechanical, circulatory, or ventilatory support; or (3) use of ultrafiltration, hemofiltration, or hemodialysis.
Main Secondary Objectives
The main secondary objectives were to determine whether tezosentan reduced the incidence of death or major cardiovascular events at 30 days, improved hemodynamic measures over the first 24 hours (in the subset of patients with a pulmonary artery catheter in place for clinical indications), reduced the 
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Statistical Analyses
The primary outcome in the individual studies, area under the curve of the change of the dyspnea score from baseline over the first 24 hours of treatment, was analyzed as a normally distributed variable (with an expected standard deviation of 600 mm·h). The null hypothesis was tested by means of the t test against an alternative of a mean difference of at least 150 mm·h for the active group compared with placebo. The primary outcome in the 2 studies combined, incidence of death or worsening heart failure, was analyzed as a binomial variable. The null hy- Table 1 (13) 70 (12) 70 (11) 70 ( (60) 222 (61) 222 (62) 191 (55) Women 147 (40) 139 (39) 138 (38) 156 (45) Race White 327 (89) 318 (88) 301 (84) 288 (83) Black 31 (8) 30 (8) 22 (6) 28 (8) Other 10 (2) 13 (4) 37 (10) 31 (9) Criteria for inclusion Pulmonary congestion Clinical examination 327 (89) 329 (91) 323 (90) (26) 91 (25) 54 (15) 46 (13) Cause of heart failure Ischemic 269 (73) 257 (71) 234 (65) 210 (61 (13) 72 (15) 72 (14) 72 (14) Heart rate, beats per min 81 (17) 82 (18) 82 (18) 84 (17 (10) 30 (12) 28 (10) 30 (12) No. with LVEF measurement 195 193 195 196 Laboratory assessments, mean (SD) Serum sodium, mEq/L 139 (4) 139 (4) 139 (7) 139 (4) (23) 84 (23) 51 (14) 45 (13) Stroke 63 (17) 49 (14) 64 (18) 60 (17) (continued) pothesis was tested using the Fisher exact test against the alternative of a risk reduction of 25% when the active group was compared with placebo (which was expected to have an event rate of 35%). The overall type I error of .05 in the VERITAS program was split, with .0008 attributed to the analysis of the individual studies (.04 to each) and .0492 (or .0092 using a more restrictive overall type I error of .01) to the combined studies. The intent was to submit the VERITAS program for registration with the US Food and Drug Administration for marketing approval if the end point of death or worsening heart failure reached a significance level of less than .01 in the analysis of the combined studies or if the dyspnea end point was significant at less than .04 in the analysis of each individual study (VERITAS-1 and VERITAS-2) or if the end point of death or worsening heart failure was significant at an overall ␣ of .05. Based on the above conditions and a 90% power for each of the coprimary end point analyses, the required sample size was estimated to be 1760 patients (440 in each group of the 2 studies). Analysis was by intention-to-treat.
Interim analyses of the coprimary end points were planned to be performed after 50% and 75% of patients had been randomized. The DSMB could recommend discontinuation of the study (for futility) if it was evident at interim analysis that neither of the objectives of the program could be fulfilled. Termination would be advised if the conditional power (calculated using the method of stochastic curtailing) fell below 10% for both death or worsening heart failure at 7 days (at ␣ = .05) and dyspnea (at ␣ = .04 for each study).
14 These conditions were fulfilled at the second interim analysis, and randomization was stopped on November 6, 2004 . Analyses were performed using SAS version 8.1 (SAS Institute Inc, Cary, North Carolina).
RESULTS
Between April 11, 2003, and January 20, 2005 , 1448 patients were randomized and evaluated at 110 sites in Australia, Europe, Israel, and North America: 735 patients at 53 sites in VERITAS-1 and 713 at 57 sites in VERITAS-2. Due to early termination of the trials for futility, only 82% of the planned number of patients (1760) was enrolled. Flow of patients through the trials is summarized in Figure 1 .
Baseline Characteristics
The treatment groups were well balanced in all respects. Of the 1435 patients who received treatment as assigned, 855 (60%) were men; the mean age of patients was 70 years. Heart failure was present before admission in 1045 (73%), and 750 (52%) had a prior history of myocardial (17) 64 (18) 62 (17) 76 (22) Calcium antagonist 57 (16) 45 (13) 47 (13) 57 (16) Amiodarone 45 (12) 52 (14) 43 (12) 27 (8) Angiotensin receptor blocker 39 (11) 37 (10) 36 (10) 34 (10) Medical treatment (intravenous) Nitrate 61 (17) 57 (16) 50 (14) 53 (15
Furosemide-equivalent dose of intravenous diuretic, mean (SD), mg b
112 (93) 113 (113) 108 (111) 98 ( infarction; 1139 (79%) had a history of hypertension, and the mean systolic blood pressure at baseline was 132 mm Hg ( 
Treatment at Baseline
As planned, all patients received an intravenous direutic. An angiotensinconverting enzyme inhibitor or angiotensin receptor blocker was used at the time of randomization in 909 (63%), a ␤-blocker in 671 (47%), and spironolactone in 265 (19%). Very few patients received other intravenous vasoactive agents at baseline or during infusion of study drug: 221 (15%) received nitrates at baseline (20% during study drug infusion), 26 (1.8%) received dobutamine(3.3%), 7 (0.5%) received nitroprusside (1.1%), 21 (1.5%) received nesiritide (2.9%), 29 (2.0%) received dopamine (4.5%), and 2 (0.1%) received milrinone (0.6%).
Study Drug Administration
Study drug was received as assigned by 727 of 730 (99.6%) patients assigned to receive tezosentan and 708 of 718 (98.6%) assigned to receive placebo ( Figure 1 ). The median time from admission to the start of study drug was 11 hours. At least 24 hours of treatment was received by 661 of 727 (91%) patients given tezosentan and 665 of 708 (94%) given placebo.
Change in Dyspnea
The mean (95% CI) VAS score for dyspnea at baseline was 66.5 (64.2 to 68.8) in the tezosentan group and 63.7 (61.5 to 65.9) in the placebo group at baseline in VERITAS-1; the corresponding scores in VERITAS-2 were 60.3 (57.7 to 62.9) and 59.4 (56.7 to 62.0), respectively, where a higher score indicated greater dyspnea. The level of dyspnea decreased rapidly in both treatment groups after randomization (FIGURE 2). The coprimary end point of the area under the curve of the change in dyspnea from baseline was similar in each treatment group in both VERITAS-1 and VERITAS-2. In VERITAS-1, the mean (95% CI) change was −562 (−628 to −497) mm·h in the tezosentan group and −550 (−617 to −483) in the placebo group (difference between treatments, −12 [−105 to 81] mm·h; P=.80). In VERITAS-2, the corresponding change in the tezosentan group was −367 (−432 to −302) mm·h and in the placebo group was −342 (−410 to −274) (difference between treatments, −25 [−119 to 69] mm·h; P=.60).
There was no difference between tezosentan and placebo in key unplanned subgroups (FIGURE 3) . The response in patients with baseline VAS scores for dyspnea above and below the median (65 mm) was similar. Similarly, a preplanned exploratory analysis of the change in rate of respiration (area under the curve analysis) showed no difference between tezosentan and placebo; in VERITAS-1 and VERITAS-2 combined, the mean (95% CI) change in the tezosentan group was −32 (−50 to −15) breaths/min·h and in the placebo group was −26 (−43 to −9) (difference between treatments, −6.4 [−31 to 18]; P=.61).
The mean (95% CI) change in the area under the curve for dyspnea change did not differ between treatment groups in the subset of 84 patients monitored hemodynamically (treatment difference, −5 [−328 to 318]; P=.97), and the treatment difference did not differ significantly between patients who were and were not monitored hemodynamically (P=.89 for interaction).
Death or Worsening Heart Failure Up to 7 Days
The incidence of the coprimary end point of death or worsening heart failure up to 7 days from randomization in VERITAS-1 and VERITAS-2 combined is shown in TABLE 2. In both treatment groups, 26% of patients experienced this composite outcome (odds ratio, 0.99; 95% CI, 0.82 to 1.21; P=.95). The effect of tezosentan compared with placebo was similar across a range of unplanned subgroups, including those defined by sex, age, etiology, LVEF, comorbidity, baseline blood pressure, and renal function and concomitant treatment.
Secondary and Exploratory End Points
The secondary end point of the incidence of death or worsening heart failure up to 30 days was 32% in the tezosentan group and 33% in the placebo group (Table 2 ). The incidence of the composite outcome of death or a major cardiovascular event at 7 days and 30 days is summarized in Table 2 .
The mean (SD) number of days spent in hospital during the index admission after randomization was 9 (7) in both treatment groups and from randomization to day 30 was 11 (8) in each treatment group.
The number of deaths at 6 months was 104 (14.3%) in the tezosentan group and 101 (14.3%) in the placebo group (hazard ratio, 1.01; 95% CI, 0.77 to 1.33).
Changes in Hemodynamic Measurements
Changes in key hemodynamic measurements at 3, 6, and 24 hours from start of study drug were secondary end points and are summarized in TABLE 3. Greater decreases in PCWP, right atrial pressure, and pulmonary and systemic vascular resistance and a trend to a greater increase in cardiac index were observed in the tezosentan group. By 24 hours, the mean (SD) decrease in systolic blood pressure was 14.6 (18.3) mm Hg in the tezosentan group and −8.5 (21.1) mm Hg in the placebo group, a statistically significant difference of −6.1 (95% CI, −8.2 to −4.1) mm Hg (P Ͻ .0001). The mean (SD) decrease in diastolic blood pressure was −9.7 (13.7) mm Hg in the tezosentan group and −4.4 (14.3) mm Hg in the placebo group, a statistically significant difference of −5.3 (95% CI, −6.7 to −3.8) mm Hg (PϽ .0001).
Safety and Adverse Effects
Of 727 tezosentan-treated and 708 placebo-treated patients, 103 (14.2%) and 68 (9.6%), respectively, stopped the study drug because of an adverse effect (P=.008). This difference was mainly due to hypotension (leading to discontinuation in 60 [8.3%] in the tezosentan group and 33 [4.7%] in the placebotreated group, P=.003), which was the most common adverse effect associated with discontinuation. Overall, hypotension up to 5 days after study drug initiation was reported as an adverse effect in 165 of tezosentan-treated patients (22.7%) and 103 placebo-treated pa- 
a Comparison between treatment groups (Fisher exact test): P = .95 at day 7 and P = .61 at day 30. b Ranked by severity; each patient counted once (as the most serious event); separate analyses for days 7 and 30, ie, a patient in cardiogenic shock on day 6 who died on day 8 was categorized as having cardiogenic shock in the day 7 analysis and as a death in the day 30 analysis. Patients who had received a heart transplant or were lost to follow-up were counted as treatment failure. c Comparison between treatment groups (Fisher exact test): P = .95 at day 7 and P = .66 at day 30. d Each patient could have more than 1 event. TEZOSENTAN AND OUTCOMES IN ACUTE HEART FAILURE tients (14.5%) (PϽ.001). At 72 hours, the mean increase in serum urea concentration in the tezosentan group was 1.7 (5.0) mmol/L; in the placebo group, it was 1.5 (6.2) mmol/L (mean difference, 0.2; 95% CI, −0.4 to 0.8; P=.58). For the same time point, the mean increase in serum creatinine concentration was 0.09 (0.35) mg/dL in the tezosentan group and 0.07 (0.32) mg/dL in the placebo group (mean difference, 0.02; 95% CI, −0.02 to 0.05; P=.39).
COMMENT
In VERITAS, low-dose tezosentan did not improve dyspnea in patients studied early after an unplanned admission to hospital with acute heart failure, nor did it improve their subsequent risk of death or nonfatal cardiovascular events. The dose of tezosentan used in VERITAS was chosen on the basis of a careful placebo-controlled doseranging study that showed this dose to reduce PCWP and systemic vascular resistance as well as plasma concentrations of BNP. 13 These hemodynamic actions were confirmed in VERITAS by the reduction in blood pressure and, in a subset of patients, PCWP.
Why did tezosentan fail to improve dyspnea in VERITAS, despite evidence of improved hemodynamics? The reduction in PCWP in the small subset of VERITAS patients with a pulmonary artery catheter was of a similar magnitude to that produced by tezosentan in past studies. 9, 12, 13 More importantly, it was also similar to the change in PCWP observed in trials of levosimendan and nesiritide, in which both of those drugs reduced dyspnea in invasively monitored patients. 15, 16 It is possible, however, that the hemodynamic effect of the dose of tezosentan used was less in the nonmonitored patients in VERITAS. Tezosentan also reduced dyspnea and PCWP more than placebo in patients monitored invasively in the Randomized Intravenous Tezosentan 2 (RITZ-2) study (n=292). Inclusion required a low cardiac index (Յ2.5) and an increased PCWP (Ն15 mm Hg). Although a larger dose of tezosentan (50 or 100 mg/h) was infused in RITZ-2 than in VERITAS (1 mg/h), the effect of tezosentan on PCWP in RITZ-2 (placebo-corrected mean reduction, 4.1 mm Hg) was similar to that in the subset of patients that underwent invasive hemodynamic monitoring in VERITAS (placebo-corrected mean reduction, 3.3 mm Hg). 17 One proposed explanation for the apparent discrepancy between VERITAS and these prior trials is that knowledge of hemodynamic changes in some way influenced the assessment of dyspnea. 18 In 1 trial of nesiritide that did not require invasive hemodynamic monitoring, neither dose of nesiritide improved dyspnea more than usual therapy. 16 Furthermore, in the larger RITZ-1 trial, in which patients (n = 669) did not undergo invasive hemodynamic monitoring, treatment with tezosentan (50 mg/h) did not improve dyspnea. 19 Similarly, in a large placebo-controlled trial of levosimendan that did not require hemodynamic monitoring, there was no apparent improvement in dyspnea. 20 In another trial, Vasodilation in the Management of Acute Congestive Heart Failure (VMAC), nesiritide (but not glyceryl trinitrate) improved dyspnea at 3 hours, but a Food and Drug Administration review concluded that this difference was driven by the subset of patients monitored hemodynamically.
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The results of 3 additional trials, however, seem to refute the hypothesis that knowledge of hemodynamic changes may influence the assessment of dyspnea, though comparison of studies with and without monitoring is only available for nesiritide, tezosentan, and levosimendan. In the Randomized Multicenter Evaluation of Intravenous Levosimendan Efficacy (REVIVE) trial, levosimendan was reported to improve dyspnea compared with placebo, but further details on the proportion of patients monitored invasively, and the change in dyspnea in these compared with nonmonitored patients, have not yet been presented. 23 In addition, 2 recent, large, placebo-controlled trials showed that the arginine vasopressin antagonist tolvaptan improved patient-reported dyspnea, apparently without investigator knowledge of hemodynamics. 24 An alternative explanation is that the potentially beneficial effect on breathlessness of reducing PCWP with tezosentan may have been offset by another, detrimental, action of endothelin blockade, for example, induction of pulmonary venous-arterial shunting leading to desaturation.
We do not think other factors explain the difference in findings between VERITAS and the "positive" trials of nesiritide and levosimendan. The patients in VERITAS were generally similar although somewhat older, and a higher proportion had preserved LVEF. However, the effect of tezosentan was similar in all subgroups, including those defined by age and LVEF. The subgroup that underwent hemodynamic monitoring in VERITAS had the same baseline PCWP as patients in the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE). 25 The VAS has been shown to be a more sensitive and reproducible measure of change in dyspnea than the Likert and Borg scales, albeit in a setting other than acute heart failure. 26 It is of concern, however, that assessment of the key symptom in acute heart failure, dyspnea, has been so poorly studied. It is also a major methodological limitation of trials in acute heart failure that the large improvement in dyspnea in the placebo group (ie, in response to usual care) makes it very difficult to detect any additional effect of new treatments with the most commonly used instruments, ie, the VAS and Likert scales. In the recent tolvaptan studies, a patient-reported score for dyspnea was used, and this did detect a difference between active treatment and placebo. 24 Understanding whether the efficacy differs among these different instruments for assessing breathlessness will be important for the conduct of future trials in this area.
Tezosentan also had no effect on the primary mortality/morbidity composite outcome (or any of the secondary outcomes), though even with this end point we had 80% power to detect a 25% relative risk reduction. Although disappointing and contrary to expectations based on the potential pathophysiological role of endothelin-1 in heart failure, our findings are consistent with earlier trials in chronic heart failure. [27] [28] [29] [30] In those trials, long-term treatment with oral endothelin receptor antagonists had no effect on left ventricular remodeling or clinical outcomes. [27] [28] [29] [30] Conceptually, however, short-term intravenous administration of a drug might have less prospect of showing a longer-term effect on morbidity and mortality outcomes, emphasizing the difficulty in evaluating new treatment for acute heart failure. Despite its hemodynamic actions, milrinone did not reduce morbidity and mortality in Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF), and nesiritide does not reduce morbidity or mortality in acute heart failure. [31] [32] [33] Of course, it is also possible that a beneficial effect of tezosentan in one subgroup of patients may have been offset by harm in another, eg, patients with a low baseline blood pressure. VERITAS did not, however, have the statistical power for such an analysis, which in any case could only be hypothesis-generating.
In summary, tezosentan, a treatment with "favorable" hemodynamic actions, failed to improve breathlessness or reduce fatal and nonfatal cardiovascular events in patients following an emergency admission to hospital with acute heart failure. So far, it has proved impossible to identify a therapeutic role for endothelin antagonists in patients with acute or chronic heart failure.
